Learning from clinical trials of neoadjuvant checkpoint blockade

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome

(2019) Jing Liu et al.   OncoImmunology

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

(2019) Alexander C. Huang et al.   NATURE MEDICINE

Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma

(2019) B. Schermers et al.   BRITISH JOURNAL OF SURGERY

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy

(2019) Martine Bloemendal et al.   ANNALS OF SURGICAL ONCOLOGY

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

(2019) Mauro Poggio et al.   CELL

The promise of neoadjuvant immunotherapy and surgery for cancer treatment

(2019) Jake S O'Donnell et al.   CLINICAL CANCER RESEARCH

Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.

(2019) Irene Reijers et al.   JOURNAL OF CLINICAL ONCOLOGY

Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).

(2019) Alexander M. Menzies et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.

(2019) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

(2019) Leonie Voorwerk et al.   NATURE MEDICINE

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

(2019) Rodabe N Amaria et al.   LANCET ONCOLOGY

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

(2019) Elisa A Rozeman et al.   LANCET ONCOLOGY

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

(2019) Georgina V Long et al.   LANCET ONCOLOGY

904PDPre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO)

(2019) M S Van der Heijden et al.   ANNALS OF ONCOLOGY

1313PD3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)

(2019) C U Blank et al.   ANNALS OF ONCOLOGY

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

(2019) Julie E Stein et al.   CLINICAL CANCER RESEARCH

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

(2018) M T Tetzlaff et al.   ANNALS OF ONCOLOGY

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

(2018) T R Cottrell et al.   ANNALS OF ONCOLOGY

CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy

(2018) Ryuma Tokunaga et al.   CANCER TREATMENT REVIEWS

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

(2018) Jan P. Böttcher et al.   CELL

It's Time to Reverse our Thinking: The Reverse Translation Research Paradigm

(2018) Valentina Shakhnovich   CTS-Clinical and Translational Science

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

(2018) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

(2018) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial).

(2018) Maria Gonzalez et al.   JOURNAL OF CLINICAL ONCOLOGY

NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.

(2018) Adi Diab et al.   JOURNAL OF CLINICAL ONCOLOGY

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

(2018) Gang Chen et al.   NATURE

Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy

(2018) Thibault Le Bourgeois et al.   Frontiers in Oncology

Cancer Neoantigens

(2018) Ton N. Schumacher et al.   Annual Review of Immunology

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

(2018) Aung Naing et al.   CANCER CELL

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

(2018) Richard W. Joseph et al.   CLINICAL CANCER RESEARCH

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

(2018) Rodabe N. Amaria et al.   NATURE MEDICINE

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

(2018) Christian U. Blank et al.   NATURE MEDICINE

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire

(2018) Ahmad Tarhini et al.   Journal for ImmunoTherapy of Cancer

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

(2017) Jacob Schachter et al.   LANCET

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

(2017) Steven Lemery et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Mutational Burden and Response Rate to PD-1 Inhibition

(2017) Mark Yarchoan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma

(2017) Jenny H. J. Lee et al.   Pigment Cell & Melanoma Research

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One

(2017)   Journal for ImmunoTherapy of Cancer

Correlation between baseline characteristics and clinical outcome of patients with advanced melanoma treated with pembrolizumab (PEMBRO)

(2016) Y. Jansen et al.   ANNALS OF ONCOLOGY

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells

(2016) Almut Brand et al.   Cell Metabolism

Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers

(2016) Marie-Caroline Dieu-Nosjean et al.   IMMUNOLOGICAL REVIEWS

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

(2016) Alexander M.M. Eggermont et al.   NEW ENGLAND JOURNAL OF MEDICINE

The "cancer immunogram"

(2016) C. U. Blank et al.   SCIENCE

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

(2016) J. Liu et al.   Cancer Discovery

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

(2016) Marcel A. Deken et al.   OncoImmunology

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

(2015) Santiago Zelenay et al.   CELL

Metabolic plasticity of human T cells: Preserved cytokine production under glucose deprivation or mitochondrial restriction, but 2-deoxy-glucose affects effector functions

(2015) Kathrin Renner et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination

(2015) Rama S. Akondy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review

(2015) Shiva Shrotriya et al.   PLoS One

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

(2014) Xiaozhou Fan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy

(2013) S. Lorenzen et al.   ANNALS OF ONCOLOGY

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Correlation of Pathologic Complete Response with Survival After Neoadjuvant Chemotherapy in Bladder Cancer Treated with Cystectomy: A Meta-analysis

(2013) Fausto Petrelli et al.   EUROPEAN UROLOGY

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

(2012) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer

(2012) In Ja Park et al.   JOURNAL OF CLINICAL ONCOLOGY

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

(2011) James S. Wilmott et al.   CLINICAL CANCER RESEARCH

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs

(2009) Emmanuelle Pradelli et al.   INTERNATIONAL JOURNAL OF CANCER

The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response

(2009) R. S. Akondy et al.   JOURNAL OF IMMUNOLOGY

Anti-CTLA-4 therapy results in higher CD4+ICOShiT cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

(2009) Hong Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non-Small Cell Lung Cancer

(2008) K. I. Al-Shibli et al.   CLINICAL CANCER RESEARCH

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY